AAP
XBIT icon

Arax Advisory Partners’s XBiotech XBIT Stock Holding History

Arax Advisory Partners’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35 Buy
+15
New +$36 ﹤0.01% 3686
2025
Q4 		– Sell
-22
Closed -$58 – 4572
2025
Q3 		$58 Buy
+22
New +$65 ﹤0.01% 3527

Other funds holding XBIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arax Advisory Partners's XBIT Position: Q1 2026 in Review

Arax Advisory Partners opened a new position in XBiotech (XBIT) in Q1 2026: 15 shares worth $35. The stake represents ﹤0.01% of the portfolio and ranks #3686 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in XBIT as recently as Q3 2025.

Arax Advisory Partners first reported a position in XBIT in Q3 2025 and has held it in 2 quarters since. The position peaked at $58 in Q3 2025. 37 funds tracked by Wall St. Rank hold XBIT as of Q1 2026.

  • Arax Advisory Partners held 15 shares of XBiotech worth $35 as of Q1 2026.
  • XBiotech was a new Arax Advisory Partners position in Q1 2026.
  • XBiotech made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3686 holding.
  • Arax Advisory Partners first reported a position in XBiotech in Q3 2025 and has held it in 2 quarters since.
  • Arax Advisory Partners's XBiotech position peaked at $58 in Q3 2025.
  • 37 funds tracked by Wall St. Rank held XBiotech as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.